The World Sleep Congress 2023 Released An Abstract Submitted By Centessa Pharmaceuticals Containing Preclinical Data On ORX750 For Narcolepsy, Other Sleep Disorders, Data Shows ORX750 Promotes Wakefulness, Reduces Cataplexy In The Orexin/Ataxin-3 Mouse
Portfolio Pulse from Benzinga Newsdesk
The World Sleep Congress 2023 has released an abstract submitted by Centessa Pharmaceuticals containing preclinical data on ORX750 for narcolepsy and other sleep disorders. The data shows that ORX750 promotes wakefulness and reduces cataplexy in the Orexin/Ataxin-3 mouse.
August 24, 2023 | 10:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Centessa Pharmaceuticals' preclinical data on ORX750 shows promising results for narcolepsy and other sleep disorders, which could potentially boost the company's stock.
The release of promising preclinical data on a company's product often leads to increased investor confidence and a potential rise in the company's stock. In this case, Centessa Pharmaceuticals' ORX750 has shown to promote wakefulness and reduce cataplexy in preclinical trials, which could potentially lead to a rise in the company's stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100